Journal
JOURNAL OF DIABETES AND METABOLIC DISORDERS
Volume 20, Issue 2, Pages 2121-2128Publisher
SPRINGER INT PUBL AG
DOI: 10.1007/s40200-021-00899-9
Keywords
Type 2 diabetes; Obesity; Incretin; Glucagon-like peptide-1 receptor agonists; Body weight
Categories
Ask authors/readers for more resources
Switching to semaglutide resulted in significant reductions in HbA1c and body weight among patients with type 2 diabetes, along with improvements in lipid metabolism parameters. Semaglutide showed promising efficacy in both patients who switched from other GLP-1 RAs and those who were semaglutide-naive.
Purpose Evidence of the efficacy and safety of semaglutide among patients with type 2 diabetes who were initiated on or were switched to semaglutide from other GLP-1 RAs remains limited. The objective of this study was to investigate the short-term effects of switching to semaglutide from other GLP-1 RAs. Methods This retrospective cohort study evaluated patients with type 2 diabetes who were initiated on or were switched to semaglutide due to poor diabetes control with other GLP-1 RAs or other medications, or obesity. HbA1c, body weight, serum creatinine, serum uric acid, parameters of lipid metabolism, and parameters of liver function were measured before and 6 months after administration of semaglutide. Results A total of 50 patients were registered in the study. After switching to semaglutide (n = 43), HbA1c and body weight significantly decreased (p < 0.01, p < 0.01), respectively. The same findings were observed in semaglutide-naive patients (p = 0.04, p < 0.02) (n = 7). Serum uric acid, total cholesterol, triglycerides, and urinary albumin-creatinine ratio decreased significantly as well (p = 0.04, p = 0.04, p = 0.02, p = 0.04), whereas serum creatinine did not change significantly (p = 0.51). Conclusions Semaglutide showed excellent efficacy, even in patients switched from other GLP-1 RAs. Semaglutide appears to be a promising agent for blood glucose and body weight control in obese type 2 diabetes mellitus patients and could be more potent in treating type 2 diabetes than existing GLP-1 RAs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available